News from relmada therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 27, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Jul 16, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Jun 29, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Jun 15, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at 2015 BIO International Convention

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Jun 10, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today...

May 27, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

May 19, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

May 12, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Apr 21, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Commences Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Apr 16, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Receives Health Canada Clearance to Further Explore Promising NMDA Receptor Antagonist d-Methadone (REL-1017)

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today...

Apr 08, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Appoints Lisa Nolan, Ph.D. as Senior Vice President of Business Development

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced...

Mar 24, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Mar 17, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Reports Positive Phase 1 Results for NMDA Receptor Antagonist d-Methadone

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Mar 12, 2015, 09:51 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at Future Leaders in the Biotech Industry Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced...

Mar 05, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Mar 03, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at ROTH Capital Partners 27th Annual Growth Stock Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Feb 24, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced...

Feb 09, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Feb 04, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Selects MepiGel Formulations to Advance Into Clinical Studies

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Jan 16, 2015, 08:30 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...